The year of 2022 will be remembered as one that ushered in a new era of diabetes management. With the approvals of tirzepatide and teplizumab dominating headlines, several other advances in the field caught the attention of millions and became topics of discussion. To celebrate the end of 2022 and the advances witnessed in the past year, our editorial team has created a list of the top 8 most popular pieces of content from 2022.
Beginning on June 7, tirzepatide (Mounjaro) will be available in US pharmacies, according to an announcement by Eli Lilly and Company.
Announced on the final day of the American Diabetes Association (ADA) 82nd Scientific Sessions, Eli Lilly and Company noted the dual GIP/GLP-1 receptor agonist, which received approval from the US FDA as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, will be made available 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg doses.
After new data from the Diabetes Prevention Program Outcomes Study suggested neither metformin nor lifestyle intervention addressed the cardiovascular risk in patients with prediabetes, we asked experts at ADA 2022 if it was time to rethink metformin as first-line therapy in type 2 diabetes.
The American Diabetes Association has released their updated Standards of Care for 2023 with the goal of providing the diabetes care team within an overview of diabetes management, including updates in diabetes technology, obesity, hypertension, heart failure medication, and lipid management.
The 2023 version of the living document, which has been updated annually since 1989, contains more than 100 updated recommendations within its 17 sections, with new updates highlighting the latest advances in clinical aspects of diabetes management, such as pharmacologic approaches to glycemic treatment, but also related to holistic diabetes management, including patient-first language and the influence of social determinants of health.
The Dexcom G7 Continuous Glucose Monitoring (CGM) System rollout began on October 4 with the company announcing its availability for people with diabetes aged 2 years and older in the United Kingdom, Ireland, Germany, Austria, and Hong Kong, with a rollout in New Zealand and South Africa expected within the following weeks.
A formal task analysis conducted in older adults with type 2 diabetes provides insight into the ease of use and task burden associated with uptake of the Dexcom G7 CGM system, with results indicating use of the system required fewer than half as many steps to initiate as previous generations of the CGM system.
An analysis comparing prescribing practices for Medicare Advantage beneficiaries against those in fee-for-service programs suggests Advantage patients were more likely to receive ACE inhibitors or ARBs, but 20% less likely to receive GLP-1 RAs and 9% less likely to receive SGLT2 inhibitors.
After demonstrating efficacy and safety as a weight loss agent in randomized clinical trials, a retrospective cohort study from a Mayo Clinic-led team is providing insight into the real-world effects of 2.4 mg semaglutide (Wegovy) for weight management.
With data from more than 150 patients treated at a referral center for weight management prescribed semaglutide for 3 months or more between January 1, 2021-March 15, 2022, results of the study suggest the mean weight loss achieved at 3 months was 5.9% of body weight, with this improving to 10.9% at 6 months and further analysis indicating more than 50% of semaglutide users achieving weight loss of 10% or more at 6 months.
The North American Menopause Society has announced the release of a new position statement outlining the organization’s stance on hormone therapy.
Published on July 7, the statement was published with the intent of providing clinicians and patients with an update to the organization’s 2017 position statement on the same topic and has been endorsed by more than 20 international organizations, including the American Association of Clinical Endocrinology and the American Medical Women’s Association.